Rejected at 1:40 a.m. Nov, 01, 2023 ] by Ahmed7
Author: al099
Related Note: 1487640068745
Rationale for change

uWorld (id:315) says "The primary effect of prostaglandin D2 (PGD2), which is released by mast cells, is bronchoconstriction. Inhibitors of either lipoxygenase (eg, zileuton) or PGD, may be used as bronchodilators in asthma treatment, but they are not useful in facilitating PDA closure."

Rejection reason

nothing about bronchoconstriction in this card, okay for now, can resubmit for more commentary from community

Text Text
Extra
Vaso-DIE-lation

- Vasodilation at arterioles
- Increased permeability at postcapillary venules
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid

Sketchy
Empty field
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
Watch associated Bootcamp video - Acute Inflammatory Response

Watch associated Bootcamp video - Inflammatory Response: Acute Inflammatory Response (Pathology)
OME

Additional Resources
One by one
Empty field
#AK_Step1_v12::#OME_banner #AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Immunology_+_General_Pathology::Pathoma_Chapter_2_(Inflammation) #AK_Step1_v12::#Pathoma::02_Inflammation::01_Acute_Inflammation::1 #AK_Step1_v12::#FirstAid::11_Musculoskeletal_Skin_and_Connective_Tissue::04_Pharm::01_Arachidonic_acid_pathways::*Pathoma_Ch_2 !AK_UpdateTags::Step1decks::Zanki-Step-Decks::Zanki-Immunology+General-Pathology::Pathoma-Chapter-2-(Inflammation) #AK_Step1_v12::#Bootcamp::Immunology::03_Inflammatory_Response::01_Acute_Inflammatory_Response #AK_Step1_v12::#B&B::16_Pathology::01_General::06_Inflammation_Principles #AK_Step1_v12::^Other::^HighYield::3-HighYield-temporary #AK_Step1_v12::#Bootcamp::Pathology::01_Inflammatory_Response::01_Acute_Inflammatory_Response #AK_Step1_v12::#FirstAid::04_Pathology::02_Inflammation::04_Acute_inflammation::02_Mediators::*Arachidonic_Acid